プレグネノロンは,大麻中毒から脳を保護することができます
Monique Vallée1, Sergio Vitiello, Luigi Bellocchio
1INSERM, Neurocentre Magendie, Physiopathologie de la Plasticité Neuronale, U862, F-33000 Bordeaux, France.
まとめ
ステロイドホルモンの前駆体であるプレグネノロンは,CB1受容体を阻害することによってTHCの影響を軽減します. この発見は,カンナビノイド過剰活性化に対する保護性脳メカニズムを明らかにし,大麻依存症の潜在的な治療法を提供しています.
科学分野:
- 神経内分泌学の神経内分泌学
- カンナビノイドの薬理学
背景:
- プレグネノロンは,すべてのステロイドホルモンの前駆体です.
- その機能的な役割は,ほとんど未知のままです.
- カンナビス・サティヴァの主な活性化合物,Δ(9) - テトラヒドロカンナビノール (THC) は,脳内のCB1受容体を活性化します.
研究 の 目的:
- プレグネノロンの機能的効果を調査する.
- プレグネノロンとTHC媒介CB1受容体活性化との相互作用を解明する.
主な方法:
- CB1受容体を活性化するためにTHCを投与する.
- 脳におけるプレグネノロン合成の測定.
- THC誘発反応に対するプレグネノロンの効果の評価.
主要な成果:
- THCの投与は,脳のプレグネノロン合成を大幅に増加させる.
- プレグネノロンは,CB1受容体の特定の阻害剤として作用します.
- プレグネノロンは,THC曝露に関連するいくつかの副作用を軽減します.
結論:
- プレグネノロンとCB1受容体を含む新しいネガティブなフィードバックループは,脳を過度に活性化から保護します.
- このメカニズムは,大麻中毒と依存症の管理のための潜在的な治療戦略を提供します.
関連する概念動画
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
1.5K
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
1.5K
CNS Depressants: Alcohol and Nicotine
1.7K
Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...
1.7K
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
1.1K
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
1.1K
Drugs Affecting Neurotransmitter Synthesis
2.5K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.5K
CNS Stimulants: Psychedelic Agents
1.1K
Hallucinogens, also known as psychedelic drugs, are a class of substances known for their ability to alter perception, cognition, and emotions. Despite their profound effects on the mind, these drugs are non-addictive, setting them apart from many other abused substances. The mechanism of action of these drugs lies in their impact on the 5-HT2A receptor in the brain. Upon activation, this receptor couples to Gq-type G proteins, triggering a cascade that releases intracellular calcium. This...
1.1K
Hepatic Encephalopathy
53
DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic...
53


